

22 September 2023

HOLISTA COLLTECH REACHES SETTLEMENT WITH ASIC

1. Settlement Process

Holista Colltech Limited (ASX: HCT) (**Holista** or the **Company**) has agreed to a settlement with the Australian Securities and Investments Commission (**ASIC**) in relation to ASIC's civil penalty proceedings in the Federal Court concerning allegedly misleading statements made with respect to Holista's sanitiser product in the period from January 2020 to July 2020 during the initial stage of the COVID-19 pandemic. The final settlement is subject to Federal Court approval.

2. Company Issues

As part of the settlement, Holista consents to certain declaratory relief sought by ASIC, a joint statement of agreed facts, and a hearing being held to determine whether the further relief sought by ASIC (including the payment of any pecuniary penalty by Holista) ought to be granted by the court. The date for the further hearing has not yet been set but is expected to be 6 and 7 December 2023. Holista and ASIC have also agreed to attend a mediation in relation to the further relief sought by ASIC, prior to the further hearing, currently scheduled for 2 November 2023.

3. Dr Marnickavasagar

The Company's current Managing Director and CEO, Dr Rajen Marnickavasagar (**Dr Rajen**), was also a defendant to the ASIC proceedings and has agreed to the settlement with ASIC. As part of the settlement, Dr Rajen consents to certain declaratory relief sought by ASIC and, subject to the Court's approval, orders requiring him to pay a pecuniary penalty in the amount of AU\$150,000 and to be disqualified from managing a corporation for a period of 4 years. Dr Rajen will also contribute AU\$200,000 towards ASIC's investigation and litigation costs.

The Board is currently considering a replacement for Dr Rajen to be appointed on or before the date the ASIC orders come into effect.

Dr Rajen is a major shareholder and remains committed to the future of the Company and will make himself available to provide appropriate operational input if requested by the Board so as to assure business continuity.

Holista Colltech non-executive chairman David Deloub welcomed the conclusion of ASIC's investigation.

The Company will provide a further update to the market following the further hearing in December 2023 referred to above.

This release has been approved by the Board of Directors.

-- ENDS --

ABOUT HOLISTA COLLTECH

Holista Colltech Ltd (**Holista**) is a research-driven biotech company, a result of the merger of Holista Biotech Sdn Bhd and Colltech Australia Ltd. It is listed on the Australian Securities Exchange (**ASX:HCT**), headquartered in Perth and has extensive operations in multiple countries, including Malaysia and North America.

Holista's core business is to conduct research to find natural solutions so that people can live healthier lives. The Group holds proprietary solutions to help food manufacturers produce healthier alternatives – without use of chemicals – that do not compromise tastes and mouthfeel. Building on its partnership network and expertise, Holista has also developed sanitising solutions for individual and corporate use to control pandemic infections.